Special Issue "New Antimalarial Drugs"

Quicklinks

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (30 November 2010)

Special Issue Editors

Guest Editor
Prof. Dr. Paul D. Roepe
Department of Chemistry, Department of Biochemistry and Molecular Biology, and Program in Tumor Biology, Lombardi Cancer Center, Georgetown University, 3900 Reservoir Rd. NW, Washington, DC 20057, USA
Website: http://bouman.chem.georgetown.edu/roepe
E-Mail:

Editorial Advisor
Dr. Derek J. McPhee
Director of Chemistry, Amyris Biotechnologies, Inc., 5885 Hollis St, Suite 100, Emeryville, CA 94608, USA
E-Mail:
Phone: +1 510 450 0761 xt 718
Fax: +1 510 225 2645
Interests: organic synthesis; medicinal chemistry; biotechnology

Published Papers

Click here to see a list of 6 papers that have been published in this special issue.

Special Issue Information

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.

Planned Papers

Type of Paper: Review
Title: Expanding the Antimalarial Drug Arsenal
Authors: Brian T. Grimberg and Rajeev K. Mehlotra
Affiliation: Center for Global Health and Diseases, School of Medicine, Case Western Reserve University, Cleveland, Wolstein Research Building, #4-129, Cleveland, Ohio, USA; E-Mail: brian.grimberg@case.edu; (B.T.G.) rajeev.mehlotra@case.edu (R.K.M.)
Abstract: The number of effective and available antimalarial drugs is quickly dwindling. Mainly, a number of drug resistance-associated mutations in malaria parasite genes such as crt, mdr1, dhfr/dhps, and cytochrome b, have led to widespread resistance to all known classes of antimalarial compounds. Unfortunately, malaria parasites have started to exhibit some level of resistance even to the most recently introduced class of drugs, artemisinins, in Asia. While there is much need and interest, the antimalarial drug discovery and development pipeline remains woefully thin, and there are precious few alternatives to artemisinins. It is likely that future antimalarial treatments might come from three major areas; new combinations of existing or reintroduction of older, once effective, antimalarial drugs, repurposing of existing drugs used to treat other diseases, and from native/traditional medicinal sources. When any newly discovered effective antimalarial treatment is used by the populous, we must maintain our constant vigilance for both parasite-specific and human-related factors that may likely hamper their success - a lesson that we have learned the hard way.

Last update: 7 January 2011

Pharmaceuticals EISSN 1424-8247 Published by MDPI Publishing, Basel, Switzerland RSS E-Mail Table of Contents Alert